Johnson & Johnson Innovation announced that it is expanding its global incubator presence through a novel collaboration with the Office of the Chief Scientist in Israel and other industry partners to establish a new biotechnology incubator near Israel’s Weizmann Science Park.
In a release, the Company said that this is the latest in a series of recently announced collaborations to fuel entrepreneurship in the world’s scientific hotspots. In addition, Johnson & Johnson Innovation announced several new collaborations with academia and biotech that focus on multiple disease areas and consumer healthcare challenges. These customized collaborations are part of Johnson & Johnson Innovation’s strategy to support an international network of scientific entrepreneurs through access to laboratory facilities, scientific expertise, and funding.
Johnson & Johnson said that the new research and development collaborations span Europe and the United States and include the University of Texas MD Anderson Cancer Center, and seven biotechnology companies: California-based Assembly Pharmaceuticals, Nodality and SutroVax; London-based TopiVert; Maryland-based Intrexon; Massachusetts-based Scholar Rock; and Netherlands-based Bioceros.
An outcome of a novel collaboration among Johnson & Johnson Innovation and Johnson & Johnson Development Corp. (JJDC), the Office of the Chief Scientist in Israel, Takeda Pharmaceutical Company, and OrbiMed Israel Partners, is a public-private biotechnology incubator that will be located near the Weizmann Science Park, Rehovot, Israel.
Johnson & Johnson said that the Weizmann Science Park area is considered to be one of the foremost centers in the world for multidisciplinary research, and is the location of a Johnson & Johnson Innovation satellite office.
“A key aim of Johnson & Johnson Innovation is to find novel ways of advancing the most promising early-stage science, ” said Patrick Verheyen, Head of Johnson & Johnson Innovation, London. “The formation of the new biotechnology incubator in Israel is the product of an important collaboration between government, industry, and venture capital that demonstrates a multi-partner approach in practice. The collaboration provides a unique platform to support and advance new companies with not only funding, but also strategic advice from both venture capital and industry pharmaceutical development experts.”
The new incubator, which will be operational in early 2014, is the latest in a series of recently announced collaborations with other biotechnology incubators to fuel entrepreneurship, including Montreal-based NEOMED; Toronto-based MaRS Innovation; San Francisco- based California Institute for Quantitative Biosciences (QB3); and Boston-based LabCentral. These announcements build upon the growing success of Janssen Labs, the 40, 000 square foot flagship facility that opened in early 2012 in San Diego at Janssen’s West Coast Research Center.